胰升血糖素样肽1对新诊断糖尿病患者分泌型卷曲相关蛋白1和β-连环蛋白表达水平的影响  

Influence of GLP-1 on SFRP1 and β-catenin in newly-diagnosed type 2 diabetes patients

作　　者：王笑烨 袁景 孙峥 梁丽 Xiao-ye Wang;Jing Yuan;Zheng Sun;Li Liang(Department of Endocrinology,the People’s Hospital of Liaoning Province,Shenyang,Liaoning 110016,China)

机构地区：[1]中国医科大学人民医院(辽宁省人民医院)内分泌科,辽宁沈阳110016

出　　处：《中国现代医学杂志》2018年第13期52-56,共5页China Journal of Modern Medicine

摘　　要：目的观察新诊断糖尿病患者经胰升血糖素样肽1(GLP-1)治疗后分泌型卷曲相关蛋白1(SFRP1)和β-连环蛋白(β-catenin)表达水平的变化。方法选取2015年1~12月于该院内分泌门诊就诊或病房住院治疗的新诊断T2DM患者(T2DM组)72例和同期体检健康者(NC组)80例,收集两组入组时的临床资料和生化指标并比较。采用酶联吸附免疫法(ELISA)检测两组入组时、T2DM组经利拉鲁肽治疗12周和停药12周后的SFRP1和β-catenin的水平变化。结果 (1)T2DM组BMI、FPG、Fins、Hb A1c、HOMAIR、SFRP1及β-catenin均高于NC组,HOMA-β低于NC组;(2)与入组时比较,T2DM组治疗12周和停药12周时BMI、FPG、Hb A1c、TC、HDL-C、HOMA-IR均降低,HOMA-β升高;(3)T2DM组不同时间SFRP1和β-catenin水平比较,差异有统计学意义(F=120.633和376.649,均P=0.000),利拉鲁肽治疗12周时和停药12周时SFRP1均高于入组时(t=-9.294和-9.927,均P=0.000),β-catenin低于入组时(t=18.468和6.956,均P=0.000),且停药12周时SFRP1低于治疗12周时(t=6.355,P=0.000),β-catenin水平高于治疗12周时(t=18.129,P=0.000)。结论 GLP-1治疗新诊断T2DM患者可改善胰岛β细胞功能改善,升高SFRP1水平,降低β-catenin的水平,其原因可能与影响Wnt信号通路有关。Objective To observe the influence of glucagon-like peptide 1(GLP-1)on secreted frizzled related protein 1(SFRP1)andβ-catenin in newly-diagnosed type 2 diabetes(T2DM)patients.Methods A total of 72 patients who were newly diagnosed as T2DM and cared in the Department of Endocrinology of the People’s Hospital of Liaoning Province from January 2015 to December 2015 were recruited as T2DM group,and at the same time,80 healthy subjects without T2DM were recruited as normal control(NC)group.The clinical data and biochemical indexes were selected and compared at the beginning of the study.The levels of SFRP1 andβ-catenin at the beginning,after 12-week treatment using Liraglutide and 12 weeks after drug withdrawal were measured by enzyme-linked immunosorbent assay(ELISA).Results The levels of BMI,FPG,Fins,HbA1c,HOMA-IR,SFRP1 andβ-catenin were higher,and the HOMA-βwas lower in the T2DM group than in the NC group(P<0.05).Compared with the levels at the beginning of the study,the levels of BMI,FPG,HbA1c,TC,HDL-C and HOMA IR were reduced,the HOMA-βwas raised in the T2DM group after 12-week treatment and 12 weeks after drug withdrawal(P<0.05).There were statistically significant differences in SFRP1 andβ-catenin in the T2DM group at different time points(F=120.633 and 376.649,P=0.000);the levels of SFRP1 were higher(t=-9.294 and-9.927,P=0.000),and theβ-catenin levels were lower(t=18.468 and 6.956,P=0.000)in the T2DM group after 12-week treatment and 12 weeks after drug withdrawal than those at the beginning;and the SFRP1 level 12 weeks after drug withdrawal was lower than that after 12-week treatment(t=6.355,P=0.000),and theβ-catenin level was higher than that after 12-week treatment(t=18.129,P=0.000).Conclusions GLP-1 can improve islet beta cell function,raise the SFRP1 level and reduce theβ-catenin level,which may be related to its influence on the Wnt signaling pathway.

关 键 词：胰升血糖素样肽-1 糖尿病 分泌型卷曲相关蛋白1 Β-连环蛋白 

分 类 号：R587.1[医药卫生—内分泌]